Russell Investments Group’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-79,515
Closed -$735K 3097
2019
Q2
$735K Sell
79,515
-109,425
-58% -$1.3M ﹤0.01% 2117
2019
Q1
$2.69M Buy
188,940
+20,816
+12% +$286K 0.01% 1563
2018
Q4
$1.92M Sell
168,124
-100,618
-37% -$1.55M ﹤0.01% 1633
2018
Q3
$5.37M Sell
268,742
-20,090
-7% -$437K 0.01% 1262
2018
Q2
$7.22M Sell
288,832
-87,107
-23% -$2.1M 0.02% 1090
2018
Q1
$9.68M Buy
375,939
+135,641
+56% +$3.7M 0.02% 997
2017
Q4
$6.03M Buy
240,298
+132,555
+123% +$3.42M 0.01% 1235
2017
Q3
$3.02M Buy
107,743
+16,228
+18% +$453K 0.01% 1545
2017
Q2
$2.75M Buy
91,515
+14,874
+19% +$421K ﹤0.01% 1549
2017
Q1
$2.28M Sell
76,641
-6,856
-8% -$214K ﹤0.01% 1679
2016
Q4
$2.9M Buy
+83,497
New +$2.88M 0.01% 1600

Other funds holding TRIB

Russell Investments Group's TRIB Position: Q3 2019 in Review

Russell Investments Group sold out of Trinity Biotech (TRIB) in Q3 2019, closing a stake of 79,515 shares — an estimated $735K sold.

Russell Investments Group first reported a position in TRIB in Q4 2016 and held it in 11 quarters. The position peaked at $9.68M in Q1 2018. 29 funds tracked by Wall St. Rank hold TRIB as of Q3 2019.

  • Russell Investments Group reported no remaining Trinity Biotech position as of Q3 2019 after selling out during the quarter.
  • Russell Investments Group sold 79,515 Trinity Biotech shares in Q3 2019, an estimated $735K.
  • Russell Investments Group first reported a position in Trinity Biotech in Q4 2016 and held it in 11 quarters.
  • Russell Investments Group's Trinity Biotech position peaked at $9.68M in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2019.

Based on Russell Investments Group's 13F filing for Q3 2019, filed 1 Nov 2019.